Comparison of the effect of Citicoline on the cognitive-behavioral performance of autism spectrum patients with standard treatments

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231030059898N1

Enrollment

Registered

2023-11-08

Start date

2023-11-11

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism spectrum disorder. Autistic disorder

Interventions

Intervention 1: Intervention group: Intramuscular injection of citicoline along with standard treatments to 40 people under the age of 18 with autism. Intervention 2: Control group: receiving standard

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: Primary diagnosis of autism using MCHAT test in children under 3 years old and CARS test in children over 3 years old

Exclusion criteria

Exclusion criteria: Intractable seizures, high blood pressure, underlying diseases such as diabetes and asthma, and lack of parental consent to enter the study

Design outcomes

Primary

Measure	Time frame
MCHAT test score for under 3 years old and CARS test for over 3 years old. Timepoint: The beginning of the study and 2 months later. Method of measurement: MCHAT test for under 3 years old and CARS test for over 3 years old.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRazieh Taghizade Sarvestani

Shiraz University of Medical Sciences

zare.samane68@gmail.com+98 71 3647 4332

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026